Advances in Drug and Alcohol Research,
Год журнала:
2023,
Номер
3
Опубликована: Май 10, 2023
Cannabidiol
(CBD)
is
a
non-intoxicating
phytochemical
from
Cannabis
sativa
that
increasingly
used
to
manage
pain.
The
potential
for
CBD
ameliorate
dimensional
behavior
symptoms
occurring
in
multiple
psychiatric
disorders
was
suggested,
including
social
interaction
impairments.
To
test
this
hypothesis,
adult
male
BTBRT+Itpr3tf/J
(BTBR)
mice,
model
of
idiopathic
autism
exhibiting
preference
deficits
and
restrictive
repetitive
behaviors,
were
acutely
treated
with
vehicle
or
0.1,
1,
10
mg/kg
CBD.
Social
assessed
50
min
after
treatment,
followed
by
novelty
at
60
min,
marble
burying
75
dominance
120
min.
(10
mg/kg)
enhanced
BTBR
but
not
preference,
dominance,
serum
levels
=
29
±
11
ng/mg
3
h
post-injection.
Next,
acute
compared
treatment
serotonin
transporter
(SERT)
knock-out
since
SERT
deficiency
an
risk
factor,
their
wildtype
background
strain
controls
C57BL/6J
mice.
generally
attenuated
yet
neither
nor
affected.
These
findings
show
as
little
purified
can
enhance
mice
are
otherwise
socially
deficient.
Molecules,
Год журнала:
2023,
Номер
28(2), С. 774 - 774
Опубликована: Янв. 12, 2023
Transient
receptor
potential
vanillin
3
(TRPV3)
is
a
member
of
the
transient
(TRP)
superfamily.
As
Ca2+-permeable
nonselective
cation
channel,
TRPV3
can
recognize
thermal
stimulation
(31–39
°C),
and
it
plays
an
important
regulatory
role
in
temperature
perception,
pain
transduction,
skin
physiology,
inflammation,
cancer
other
diseases.
not
only
activated
by
changes
temperature,
but
also
be
variety
chemical
physical
stimuli.
Selective
agonists
antagonists
with
effects
physiological
functions
for
clinical
application
are
highly
demanded.
In
recent
years,
significant
progress
has
been
made
study
TRPV3,
there
still
lack
modulators
strong
affinity
excellent
selectivity.
This
paper
reviews
functional
characteristics
terms
structure,
diseases
research
on
modulators.
Antioxidants,
Год журнала:
2023,
Номер
12(2), С. 485 - 485
Опубликована: Фев. 14, 2023
The
literature
provides
scientific
evidence
for
the
beneficial
effects
of
cannabidiol
(CBD),
and
these
extend
beyond
epilepsy
treatment
(e.g.,
Lennox–Gastaut
Dravet
syndromes),
notably
influence
on
oxidative
status,
neurodegeneration,
cellular
protection,
cognitive
function,
physical
performance.
However,
products
containing
CBD
are
not
allowed
to
be
marketed
everywhere
in
world,
which
may
ultimately
have
a
negative
effect
health
as
result
uncontrolled
market.
After
isolation
follows
discovery
CB1
CB2
receptors
main
enzymatic
components
(diacylglycerol
lipase
(DAG
lipase),
monoacyl
glycerol
(MAGL),
fatty
acid
amino
hydrolase
(FAAH)).
At
same
time,
antioxidant
potential
is
due
only
molecular
structure
but
also
fact
that
this
compound
increases
expression
endogenous
systems,
superoxide
dismutase
(SOD),
glutathione
peroxidase
(GPx),
through
nuclear
complex
erythroid
2-related
factor
(Nrf2)/Keep1.
Regarding
role
control
inflammation,
function
exercised
by
inhibiting
(nuclear
kappa
B)
NF-κB,
genes
encode
molecules
with
pro-inflammatory
(cytokines
metalloproteinases).
other
performance
should
excluded.
In
conclusion,
market
needs
regulated
more
thoroughly,
given
previously
listed
properties,
mention
safety
profile
very
good
one.
Basic & Clinical Pharmacology & Toxicology,
Год журнала:
2024,
Номер
134(5), С. 574 - 601
Опубликована: Март 13, 2024
Abstract
Studies
have
demonstrated
the
neuroprotective
effect
of
cannabidiol
(CBD)
and
other
Cannabis
sativa
L.
derivatives
on
diseases
central
nervous
system
caused
by
their
direct
or
indirect
interaction
with
endocannabinoid
system‐related
receptors
molecular
targets,
such
as
5‐HT
1A
receptor,
which
is
a
potential
pharmacological
target
CBD.
Interestingly,
CBD
binding
receptor
may
be
suitable
for
treatment
epilepsies,
parkinsonian
syndromes
amyotrophic
lateral
sclerosis,
in
serotonergic
plays
key
role.
The
aim
this
review
was
to
provide
an
overview
cannabinoid
effects
neurological
disorders,
epilepsy,
multiple
sclerosis
Parkinson's
diseases,
discuss
possible
mechanism
action,
highlighting
interactions
targets
phytocannabinoids.
has
been
shown
significant
therapeutic
epilepsy
disease,
while
nabiximols
contribute
reduction
spasticity
are
frequent
option
sclerosis.
Although
there
theories
cannabinoids
substantially
greater
progress
search
strong
scientific
evidence
effectiveness
needed.
